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Disparities in Use of Human Epidermal Growth Hormone
Receptor 2–Targeted Therapy for Early-Stage Breast Cancer
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A B S T R A C T
Purpose
Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal growth factor
receptor 2 (HER2)–positive breast cancer. The rates and patterns of trastuzumab use have never
been described in a population-based sample. The recent addition of HER2 information to the SEER-
Medicare database offers an opportunity to examine patterns of trastuzumab use and to evaluate
possible disparities in receipt of trastuzumab.
Methods
We examined a national cohort of Medicare beneficiaries with incident stage I to III HER2-positive
breast cancer diagnosed in 2010 and 2011 (n = 1,362). We used insurance claims data to track any
use of trastuzumab in the 12 months after diagnosis as well as to identify chemotherapy drugs used
in partnership with trastuzumab. We used modified Poisson regression analysis to evaluate the
independent effect of race on likelihood of receiving trastuzumab by controlling for clinical need,
comorbidity, and community-level socioeconomic status.
Results
Overall, 50% of white women and 40% of black women received some trastuzumab therapy.
Amongwomenwith stage III disease, 74%ofwhites and 56%of blacks received trastuzumab. After
adjustment for tumor characteristics, poverty, and comorbidity, black women were 25% less likely
to receive trastuzumab within 1 year of diagnosis than white women (risk ratio, 0.745; 95% CI, 0.60
to 0.93).
Conclusion
Approxemately one half of patients 65 years of age and older with stage I to III breast cancer do not
receive trastuzumab-based therapy, which includes many with locally advanced disease. Significant
racial disparities exist in the receipt of this highly effective therapy. Further research that identifies
barriers to use and increases uptake of trastuzumab could potentially improve recurrence and
survival outcomes in this population, particularly among minority women.
J Clin Oncol 34:2003-2009. © 2016 by American Society of Clinical Oncology
INTRODUCTION
In the past two decades, the monoclonal antibody
trastuzumab has dramatically changed the treat-
ment paradigm and prognosis of human epi-
dermal growth factor receptor 2 (HER2)–positive
breast cancer.1-4 Since its approval for adjuvant
use in the United States in 2004, trastuzumab has
been rapidly adopted as a standard of care for
women with stage II to III HER2-positive disease
and is offered to many women with stage I breast
cancer. Although the benefits of trastuzumab are
uncertain among some patients (eg, those with
very small cancers and frail elderly patients),5
most women with HER2-positive breast cancer
benefit from trastuzumab-based systemic therapy,
which has been shown in long-term follow-up
studies to improve overall survival in this patient
population by 37%.4 However, noninitiation and
nonadherence studies have shown in the other
primary targeted therapy—endocrine therapy in
hormone receptor–positive breast cancer—that
highly effective drug therapy is not always delivered
consistently across patient populations. The actual
uptake of trastuzumab in community settings and
the extent to which trastuzumab is used or under-
used in US populations, particularly among vul-
nerable groups such asminority and elderly women,
are unknown.
The study of disparities in trastuzumab
use has been complicated by the lack of large
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population-based cohorts with known HER2 status. To date,
available observational data sources have been limited to single-
institution series and pooled data from academic centers and have
been focused primarily on the impact of trastuzumab-based
therapy on outcomes among women with stage I tumors.6-10 To
our knowledge, no prior study has described predictors of tras-
tuzumab use among eligible women with HER2-positive breast
cancer in a large population-based cohort.
Beginning in 2010, HER2 status became a required data
element for cancer registries that participate in the SEER network
of the National Cancer Institute, and these data have been made
available for cases diagnosed in 2010 and 2011. To date, this
information has been used only to describe the epidemiology of
breast cancer with regard to the triple phenotype (the combination
of estrogen receptor [ER], progesterone receptor [PR], and HER2
status) in breast cancer.11 Linkage of SEER data with fee-for-service
Medicare administrative claims offers an opportunity to examine
potential racial disparities in trastuzumab use among a national
cohort of women with HER2-positive breast cancer. We examined
racial variation in trastuzumab use among Medicare beneficiaries
with newly diagnosed nonmetastatic HER2-positive breast cancer
who are candidates for adjuvant trastuzumab-based therapy.
METHODS
Data Source and Study Population
We used data from the SEER-Medicare–linked data set for the period
2009 to 2013. SEER data represent approximately 28% of the US cancer
population. For those ages 65 years and older and insured by fee-for-
service Medicare, approximately 97% are successfully linked by the
National Cancer Institute. The SEER Medicare data are linked by using an
iterative, deterministic approach that has been described previously.12 Data
elements include demographic characteristics, timing and type of cancer
diagnosis, staging, and insurance-reimbursed treatment. Our preliminary
sample included female patients who received a diagnosis in 2010 and 2011
of a first primary stage I to III HER2-positive invasive breast cancer at age
66 years or older (to allow for assessment of comorbidity in the prior year)
and who survived at least 365 days from diagnosis. SEER registries use an
algorithm to assign HER2 status that combines available results from
immunohistochemistry, fluorescence in situ hybridization, and chromo-
genic in situ hybridization tests.13
Patients were required to have continuous enrollment in fee-for-
service Medicare parts A and B from 12 months before to 12 months after
diagnosis to ensure full capture of all treatment of comorbid conditions as
well as the first course of primary breast cancer treatment. Patients enrolled
in health maintenance organization plans were excluded due to incomplete
ascertainment of claims. Patients were required to have a primary breast
cancer surgery (either breast-conserving surgery or mastectomy) within
6 months of diagnosis from a previous methodology14 (Data Supplement).
Patients with borderline, unknown, or missing information for both ER
and PR status were excluded because they could not be classified into a
tumor phenotype (n # 11). A CONSORT diagram is shown in Figure 1.
Primary Outcome
The primary outcome was receipt of trastuzumab, which was defined
as at least one claim for trastuzumab within the year after diagnosis
(Healthcare Common Procedure Classification System code J9355).
Trastuzumab exposure could occur at any time between diagnosis and day
365 postdiagnosis, which included both neoadjuvant and adjuvant
sequencing. Chemotherapies given concurrently with trastuzumab were
examined and categorized by analyzing all claims for chemotherapy agents
given to patients within 1 year of diagnosis and categorizing as follows:
doxorubicin, cyclophosphamide, taxane (ACTH) regimen; docetaxel,
carboplatin (TCH) regimen; some doxorubicin or carboplatin use that did
not meet the definition of ACTH or TCH; taxane agents with or without
cyclophosphamide; all other chemotherapy partners; and trastuzumab as a
single agent. Detailed definitions of chemotherapy regimens can be found
in the Data Supplement. For patients who did not receive trastuzumab, use
of any chemotherapy within 1 year was also captured.
Primary Exposure and Covariates
Our primary exposure of interest was race as recorded by Medicare
enrollment files, which are based on information from the Master Ben-
eficiary Record of the Social Security Administration.15-17 We obtained key
covariates from the SEER Patient Entitlement and Diagnosis Summary
File, which included diagnosis date, age, race (white, black, other), tumor
characteristics, and ER and PR status. Tumor grade, primary tumor size,
and nodal involvement were defined according to American Joint Com-
mittee on Cancer Staging VII criteria.17a
Additional covariates defined based on claims-based algorithms were
type of breast surgery, receipt of radiation,14 and comorbidity as defined by
the Klabunde modification of the Charlson comorbidity index.18 Con-
textual socioeconomic variables were taken from American Communities
Survey data and included the proportion of people living in poverty in the
patients’ census tracts.19 We controlled for geographic variation in tras-
tuzumab use by the four-category grouping of SEER regions (northeast,
south, north central, and west).
Statistical Analysis
To identify predictors of trastuzumab use, we used modified mul-
tivariable Poisson regression analysis with sandwich standard errors20 by
using the GENMOD procedure of SAS version 9.4 software (SAS Institute,
Cary, NC). Covariates for the final model were determined a priori on the
basis of clinical judgment and literature that has identified common factors
associated with variations in breast cancer treatment. Patient-level cova-
riates of interest were chosen based on literature that breast cancer
treatment and outcomes may vary by marital status,21 comorbidity,22
socioeconomic status,23 and geographic region.24 Year of diagnosis was
included based on literature that adoption of treatment innovations
increases over time.25 Disease-related variables were chosen based on
clinical judgment about their use in treatment decision making and
prognostication, which includes tumor size, nodal status, tumor grade, and
hormone receptor status. Local therapy approach was included based on
clinical judgment that differences in local treatment preferences might be
associated with differences in systemic treatment preferences. We present
unadjusted and adjusted risk ratios (RRs) and 95% CIs for all models.
RESULTS
We identified 1,362 women with HER2-positive breast cancer
(85% white, 7.6% black, 7% other races). Table 1 shows clinical
and demographic characteristics of the cohort. Around one half of
patients were younger than 75 years, and 69% had node-negative
disease. Seventy-three percent of patients had triple-positive
(hormone-receptor and HER2-positive) breast cancer. More
than one half of patients (52%) had high-grade tumors, and 42%
had tumors$ 2 cm, which reflects the relatively aggressive biology
of HER2-positive cancer. In bivariable analyses, patients who
received trastuzumab were significantly younger, more likely to
have hormone receptor–negative disease, and more likely to be
treated surgically with mastectomy than patients who did not
receive trastuzumab.
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We examined unadjusted rates of trastuzumab use by race.
Overall, trastuzumab use within 1 year of diagnosis was 50%
among whites (n = 1,162), 40% among blacks (n = 104), and 52%
among other minorities (n = 96; data not shown). Use among
blacks compared with whites lagged at every stage (Fig 2), with
56% of blacks and 74% of whites receiving trastuzumab for stage
III disease. Due to cell sizes ,11 in black women, exact numbers
are not displayed.
Predictors of Trastuzumab Use
After adjustment for the covariates age, comorbidity, and
disease characteristics as well as type of locoregional therapy and
neighborhood-level poverty, black women were 25% less likely to
receive trastuzumab within 1 year of diagnosis than white women
(RR, 0.75; 95% CI, 0.60 to 0.93; Table 2). Disease characteristics
that predicted a greater likelihood of receiving trastuzumab were
large tumor size (all T sizes greater than T1a), node positivity, and
moderately or poorly differentiated tumors compared with well-
differentiated tumors. Age older than 74 years and the presence of
medical comorbidity measured by a Charlson comorbidity score. 1
were associated with a lower likelihood of receiving trastuzumab.
Hormone receptor positivity was not an independent predictor of
trastuzumab use after controlling for other tumor characteristics.
Women who received breast-conserving surgery and radiation as
their locoregional therapy were somewhat less likely to receive
trastuzumab (RR, 0.73; 95% CI, 0.63 to 0.86) than those treated
with mastectomy.
To address the concern that cardiac as opposed to overall
comorbidity may exert a stronger effect on the likelihood of
trastuzumab receipt and may attenuate the independent effects
of race and age, we performed sensitivity analyses for measures of
cardiac comorbidity derived from the Medicare Chronic Con-
ditions Warehouse in combination with and substituted for the
modified Charlson comorbidity score. The estimated effect of race
and age on likelihood of trastuzumab receipt remained stable
regardless of the approach to comorbidity modeling. Full results of
this analysis are presented in the Data Supplement.
Patterns of Chemotherapy Use With Trastuzumab
We performed descriptive analyses to determine the most
common chemotherapy partners for patients who received tras-
tuzumab. By using their pattern of chemotherapy drug claims, we
Women age 66 years and older,
with stage I to III HER2-positive or borderline
primary breast cancer in 2010 or 2011
(N = 3,516)
Survived at least 365 days after
diagnosis
(n = 3,365)
No surgery or surgery more
than 6 months after
diagnosis (n = 196)
Diagnosed with a second
primary within 1 year
(n = 52)
ER or PR unknown
or borderline, unknown
tumor size, or nodal status
(n = 17)
At least 1 month of HMO
coverage or at least 1
month without A and B
coverage (n = 1,347)
Died within 365 days of
diagnosis (n = 151)
FFS Medicare A and B (no HMO) from
12 months before to 12 months after diagnosis
(n = 2,018)
Mastectomy or breast-conserving
surgery within 6 months of diagnosis
(n = 1,822)
No other cancer diagnosis 
within 1 year
(n = 1,770)
Known hormone receptor (ER, PR)
status + tumor characteristics
(n = 1,753)
Available for analysis of 
HER2-positive (n = 1,362) or 
borderline (n = 391) disease
Fig 1. CONSORT diagram for study cohort.
ER, estrogen receptor; FFS, fee for service;HER2,
humanepidermal growth factor receptor 2;HMO,
health maintenance organization; PR, progester-
one receptor.
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categorized patients as having received one of the following: ACTH
OR TCH, some exposure to anthracycline or carboplatin-based
agents without meeting the predetermined criteria for ACTH or
TCH, taxane agents only, single-agent trastuzumab, and other
chemotherapy agents. Complete descriptions of the chemotherapy
algorithms are provided in the Data Supplement. Among trastu-
zumab users (n = 672), the most common chemotherapy regimen
was TCH (42% of treated patients [n = 285]) followed by taxane-only







No. % No. % No. % P
Age-group , .001
65-69 years 354 26.0 212 31.5 142 20.6
70-74 years 362 26.6 222 33.0 140 20.3
75-84 years 501 36.8 216 32.1 285 41.3
$ 85 years 145 10.6 22 3.3 123 17.8
Race .1511
Black 104 7.6 42 6.3 62 9.0
Other 96 7.0 50 7.4 46 6.7
White 1,162 85.3 580 86.3 582 84.3
State buy-in for 12 months before diagnosis .0861
No 1,163 85.4 585 87.1 578 83.8
Yes 199 14.6 87 12.9 112 16.2
SEER region .797
North central 172 12.6 81 12.1 91 13.2
Northeast 274 20.1 141 21.0 133 19.3
South 350 25.7 169 25.1 181 26.2
West 566 41.6 281 41.8 285 41.3
Marital status , .001
Married 554 40.7 255 37.9 299 43.3
Other 808 59.3 417 62.1 391 56.7
Comorbidity score , .001
0 844 62.0 451 67.1 393 57.0
1 288 21.1 126 18.8 162 23.5
$ 2 230 16.9 95 14.1 135 19.6
Residents below poverty level .1397
, 5.0% 289 21.2 160 23.8 129 18.7
5.0%-9.99% 373 27.4 178 26.5 195 28.3
10.0%-19.99% 439 32.2 212 31.5 227 32.9
$ 20.0% 261 19.2 122 18.2 139 20.1
Diagnosis year .0581
2010 684 50.2 320 47.6 364 52.8
2011 678 49.8 352 52.4 326 47.2
AJCC tumor size , .001
T1a 139 10.2 25 3.7 114 16.5
T1b 203 14.9 71 10.6 132 19.1
T1c 452 33.2 235 35.0 217 31.4
T2 452 33.2 271 40.3 181 26.2
T3 67 4.9 35 5.2 32 4.6
T4 49 3.6 35 5.2 14 2.0
AJCC nodes involved , .001
N0 942 69.2 386 57.4 556 80.6
N1 282 20.7 185 27.5 97 14.1
N2/N3 138 10.1 101 15.0 37 5.4
Tumor grade , .001
Well differentiated 124 9.1 25 3.7 99 14.3
Moderately differentiated 484 35.5 192 28.6 292 42.3
Poorly differentiated 703 51.6 439 65.3 264 38.3
Unknown 51 3.7 16 2.4 35 5.1
Hormone receptor status .0091
Positive 990 72.7 467 69.5 523 75.8
Negative 372 27.3 205 30.5 167 24.2
Surgery type , .001
Mastectomy 574 42.1 305 45.4 269 39.0
Breast conserving 324 23.8 201 29.9 123 17.8
Breast conserving and radiation 397 29.1 127 18.9 270 39.1
Mastectomy and radiation 67 4.9 39 5.8 28 4.1
Abbreviation: AJCC, American Joint Committee on Cancer.
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regimens (21% [n = 141]) and ACTH (9% [n = 58]). A small number
of women had one or more claims for an anthracycline (3% [n = 20])
or carboplatin (8% [n = 55]) but did not clearly receive ACTH or
TCH. In this sample, 94 women received trastuzumab as a single
agent, and 19 received it in combination with another nonstandard
chemotherapeutic agent. The distribution of chemotherapy regimens
is illustrated in Figure 3. Due to small sample sizes for most regimens
in minority women, racial differences in chemotherapy type were not
systematically examined.
DISCUSSION
This study found that approximately one half of women with
HER2-positive breast cancer insured by Medicare did not receive
adjuvant HER2-targeted therapy and that black women were 25%
less likely than clinically similar white women to receive such
therapy. These findings have several troubling implications. First,
although this study did not examine survival outcomes, the low
overall rates of use and low rates among patients with stage II and
III disease raise concerns for widespread underuse of trastuzumab
in this age-group. Second, the racial findings suggest that the
presence of a clear biologic predictor of treatment benefit, in this
case the HER2 marker, does not mitigate the overall pattern of
treatment disparity observed among black women with breast
cancer.26 Finally, this pattern is observed during a recent time
period (2010 to 2011) and suggests that gaps in breast cancer
treatment continue to be problematic despite widespread aware-
ness of the problem and efforts to improve access to care among
minority women.27-30
We found that older patients and those with a higher
comorbidity burden were less likely to receive trastuzumab-based
therapy following a long-standing pattern observed in studies of
systemic breast cancer treatment. In some cases, such variation
may be appropriate because small gains in recurrence-free survival
from targeted therapy may be attenuated or lost in patients with
significant competing mortality risks. However, given the sizeable
benefit of trastuzumab, the overall aggressive biology of this
subtype, and extensive literature documenting undertreatment
of even healthy older patients,31 the hypothesis that age is used
inappropriately to withhold trastuzumab-based therapy deserves
further exploration. The availability of large patient cohorts that
represent the entire age spectrum of patients with HER2-positive
disease will be key to such research.
Several aspects of trastuzumab therapy may contribute to
its underuse among minority women. First, standard use of this









































Stage I Stage II Stage III
Fig 2. Receipt of trastuzumab among women with human epidermal growth
factor receptor 2–positive breast cancer by stage and race.
Table 2. Results of Multivariable Model
Parameter and Level Risk Ratio 95% CI P
Age-group
65-69 years 1.00 Reference
70-74 years 0.98 0.88 to 1.09 .7349
75-84 years 0.74 0.65 to 0.84 , .001*
$ 85 years 0.25 0.17 to 0.37 , .001*
Race
Black 0.75 0.60 to 0.93 .0097*




Not married 0.93 0.84 to 1.03 .1537
SEER region
North central 0.90 0.77 to 1.06 .2038
Northeast 1.04 0.91 to 1.17 .5917
South 0.98 0.87 to 1.11 .7772
West 1.00 Reference
Below poverty
, 5.0% 1.00 Reference
5.0%-9.99% 0.85 0.75 to 0.97 .0155†
10.0%-19.99% 0.87 0.77 to 0.99 .0377†
$ 20.0% 0.88 0.76 to 1.02 .0965
Comorbidity score
0 1.00 Reference
1 0.90 0.80 to 1.02 .1063
$ 2 0.84 0.73 to 0.97 .0187†
Diagnosis year
2010 1.00 Reference
2011 1.12 1.02 to 1.23 .0176†
Hormone receptor status
Positive 1.00 Reference
Negative 1.04 0.94 to 1.15 .4832
AJCC tumor size
T1a 1.00 Reference
T1b 1.72 1.18 to 2.51 .0047*
T1c 2.19 1.54 to 3.12 , .001*
T2 2.30 1.62 to 3.28 , .001*
T3 2.04 1.36 to 3.05 , .001*
T4 2.58 1.75 to 3.81 , .001*
AJCC nodes involved
N0 1.00 Reference
N1 1.27 1.14 to 1.41 , .001*
N2/N3 1.36 1.19 to 1.55 , .001*
Tumor grade
Well differentiated 1.00 Reference
Moderately differentiated 1.68 1.19 to 2.38 .0034*
Poorly differentiated 2.30 1.63 to 3.23 , .001*
Unknown 1.48 0.90 to 2.44 .1199
Surgery type
Mastectomy 1.00 Reference
Breast conserving only 1.15 1.04 to 1.28 .0075*
Breast conserving and radiation 0.73 0.63 to 0.86 , .001*
Mastectomy and radiation 1.02 0.83 to 1.25 .8797
Abbreviation: American Joint Committee on Cancer.
*Significant at P , .01.
†Significant at P , .05.
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evidence for the effectiveness of less-intensive single-agent taxane
regimens for use in patients with HER2-positive breast cancer has
only recently been presented32 and was not available during this
study period. The pairing of trastuzumab with intensive chemo-
therapy and the long duration of treatment may be a barrier to the
treatment of patients with unreliable sources of transportation, job
insecurity, or poor social support, and providers may perceive such
women as less able to tolerate prolonged intensive treatment.
Although we controlled for poverty at the neighborhood level, a
complete accounting for such complex social factors is not possible
in a claims-based analysis. Second, trastuzumab is a costly infused
therapy. Although the patients in the present sample were uni-
formly insured by Medicare, the generosity of supplemental plans
for outpatient expenses and the affordability of shared costs likely
vary by race and could influence uptake. Third, the decision to use
trastuzumab-based adjuvant therapy in patients with stage I breast
cancer is made in the context of limited evidence,5 with many
patients falling into a gray zone of risk and benefit. Patients’ways of
considering and weighing this imperfect evidencemay vary by race,
and minority patients may also be treated by providers who are less
comfortable with applying the current evidence to recommend
treatment with uncertain or marginal benefit. Fourth, trastuzumab
therapy is a lengthy course of treatment that involves 1 year of
infused therapy. Previous studies have suggested that black women
are more likely to discontinue adjuvant trastuzumab therapy
early,10 and this protracted treatment course may similarly be a
disincentive to initiation of treatment of minority patients with
limited resources for obtaining and adhering to treatment. Finally,
trastuzumab is a relatively new adjuvant therapy for breast cancer,
and we and others have previously demonstrated that the adoption
of cancer treatment innovations lags among minority patients.25,33,34
Not surprisingly, we found that clinically appropriate infor-
mation, such as tumor size and nodal status, influenced the receipt
of trastuzumab. We also found an indication of increasing use at a
tumor size as small as 6 mm (T1b disease), which suggests that
providers may define this as the appropriate cut point for con-
sidering HER2-directed therapy. Furthermore, hormone receptor
status was not an independent predictor of trastuzumab use in ad-
justed analysis despite known differences in recurrence risk between
patients with hormone receptor–positive/HER2-positive and hor-
mone receptor–negative/HER2-positive disease and the availability of
additional targeted therapy, specifically endocrine therapy in the
former. However, given that hormone receptor status was associated
with trastuzumab use in bivariable analysis, the inclusion of multiple
other disease characteristics, such as grade and tumor size, in the
model likely attenuated the independent effect of hormonal status
because hormone receptor–positive tumors would also be expected
to present at a lower grade and smaller size.
In descriptive analysis, we found that trastuzumab often was
paired with chemotherapeutic agents other than ACTH and TCH,
including a significant proportion of single-agent taxane regimens.
Although weekly paclitaxel with trastuzumab is increasingly rec-
ognized as a regimen with good short-term outcomes in low-risk
HER2-positive disease on the basis of data published in 2014,32 the
current findings suggest that a significant number of providers
adopted such regimens in advance of the clinical evidence possibly
as an attempt to compromise between clinical need and toxicity con-
cerns. More of concern, we found that 14% of trastuzumab recipients
received no chemotherapeutic agent of any type, an approach that has
no evidence of efficacy in this setting. Although sample size did not
permit exploration of chemotherapy partners by race or other patient-
level factors, concerns that there may be disparities in treatment
intensity as well as trastuzumab receipt deserve further exploration.
This study has several important limitations. First, we focused
the analysis on women with HER2-positive cancer and excluded
391 with SEER-defined HER2 borderline phenotype. We hy-
pothesized that in the early period of adoption of this mandatory
data element, the borderline group would include both patients
with truly borderline clinical results and patients for whom the
registry has incomplete information with regard to HER2 status
(eg, an immunohistochemical result of 2+ without a subsequent
confirmatory test result). To explore this, we examined rates of
trastuzumab use among the HER2-positive and HER2 borderline
groups and found that overall use was 49% among HER2-positive
group but only 6% among the borderline group, which reinforces
concerns that the borderline group might include many patients
who were not ultimately determined by their treating provider to
have HER2-positive disease. Second, although we measured
comorbidity by using a validated claims-based instrument for
patients with cancer, this measure may not reflect less critical but
relevant comorbidities, such as cardiac risk factors, that might
affect chemotherapy decisions and vary by race. However, all
patients were required to have primary breast surgery, which
indicated at least some level of fitness for cancer therapy. As with
other analyses that used SEER-Medicare data, the current findings
may not represent treatment patterns among younger women or
those in Medicare-managed care plans. Finally, in a claims-based
analysis, we were not able to ascertain whether HER2-directed
therapy was offered to a patient and in what context it was dis-
cussed. Further investigations that examine prescribing behavior at
the provider level may help to clarify provider-level factors that
influence disparities.
In conclusion, trastuzumab is an innovative and nontoxic
biologic therapy with a clear biomarker for prediction of response
and ample evidence of significant improvements in survival of
patients with HER2-positive breast cancer. Its underuse among
older, particularly black, women is a concerning finding that merits
further study. System-level interventions that highlight patients
eligible for HER2-directed therapy objectively and consistently as





















Fig 3. Chemotherapies received with trastuzumab (n = 672). ACTH, doxorubicin,
cyclophosphamide, taxane; TCH, docetaxel, carboplatin.
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the patient level are needed to ensure that this effective treatment
reaches all women who will benefit.
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